|
Synonyms: EP262 | example 30 [WO2023192901] | INCB000262
Compound class:
Synthetic organic
Comment: Setomagpran (likely company research code EP262, Escient Pharmaceuticals) is a Mas-related G protein-coupled receptor MRGPRX2 antagonist/noncompetitive inverse agonist [2-3]. It inhibits basal receptor activity which confirms its inverse agonist action.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Dehn S, Cooper D, Weyer C, Ferguson B, Srinivasan S, Saint-Cyr Proulx E, Bissonnette R. (2026)
EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study. Dermatol Ther (Heidelb), [Epub ahead of print]. [PMID:42629547] |
|
2. Lanier M, Boehm M, Huang L, Martinborough E, Sainz M, Selfridge B, Yeager A. (2023)
Quinoline derivatives as modulators of mas-related g-protein receptor x2 and related products. Patent number: WO2023192901A9. Assignee: Escient Pharmaceuticals Inc. Priority date: 29/03/2023. Publication date: 14/12/2023. |
|
3. Wollam J, Solomon M, Villescaz C, Lanier M, Evans S, Bacon C, Freeman D, Vasquez A, Vest A, Napora J et al.. (2024)
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists. J Allergy Clin Immunol, 154 (4): 1033-1043. [PMID:38971540] |